Therapeutic radiopharmaceuticals in more depth — same lineup as the Therapy panel in Radiopharmaceuticals, grouped into active clinical use, clinical trials, and historical agents.
FDA-approved / routine therapeutic agents in US clinical practice.
Lu-177 DOTATATE PRRT for SSTR+ GEP-NETs.
Placeholder pageLu-177 PSMA-617 RLT for PSMA+ mCRPC.
Placeholder pageRa-223 α therapy for symptomatic CRPC bone mets.
Placeholder pageHyperthyroidism, remnant ablation, and DTC.
Placeholder pageSIRT / radioembolization for selected hepatic malignancy.
Placeholder pagePhase 3 or investigational — not FDA-approved routine care.
Phase 3 PSMA ligand (ECLIPSE) — not FDA-approved routine therapy.
Placeholder pagePhase 3 SSTR PRRT (COMPETE / DOTATOC).
Placeholder pagePhase 3 targeted α PSMA therapy — supply-limited investigational.
Placeholder pageDiscontinued or no longer commercially available in routine US practice.